| 24.98 0 (0%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.19 | 1-year : | 34.1 |
| Resists | First : | 25 | Second : | 29.19 |
| Pivot price | 24.42  |
|||
| Supports | First : | 24.2 |
Second : | 23.7 |
| MAs | MA(5) : | 24.58 |
MA(20) : | 24.37 |
| MA(100) : | 14.06 |
MA(250) : | 0 | |
| MACD | MACD : | 1.3  |
Signal : | 1.7 |
| %K %D | K(14,3) : | 72.1 |
D(3) : | 63.4 |
| RSI | RSI(14): 80.1 | |||
| 52-week | High : | 25 | Low : | 3.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PRVB ] has closed Bollinger Bands are 82.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 25.02 - 25.14 | 25.14 - 25.25 |
| Low: | 24.68 - 24.82 | 24.82 - 24.93 |
| Close: | 24.78 - 24.99 | 24.99 - 25.17 |
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Sun, 26 Mar 2023
Provention Bio: Sanofi Acquires Provention Bio With A 273% Premium (NASDAQ:PRVB) - Seeking Alpha
Mon, 13 Mar 2023
Sanofi (EPA:SQ) Agrees to Pay $2.9 Billion for Provention Bio (PRVB) - Bloomberg.com
Mon, 13 Mar 2023
Press Release: Sanofi to acquire Provention Bio, adding to - GlobeNewswire
Mon, 13 Mar 2023
Sanofi hones in on type 1 diabetes in $2.9 bln Provention Bio deal - Reuters
Mon, 13 Feb 2023
Provention Bio Announces Completion of $35 Million Equity Investment from Sanofi US - PR Newswire
Thu, 07 Jul 2022
Provention Bio Announces $60 Million Private Placement - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 6.961e+007 (%) |
| Held by Institutions | 4.6 (%) |
| Shares Short | 8,200 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2693e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -993.9 % |
| Return on Assets (ttm) | -43.1 % |
| Return on Equity (ttm) | -97.7 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 165.89 |
| Sales Per Share | 5.23984e+006 |
| EBITDA (p.s.) | -2.57805e+007 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -75 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 44.2 |
| Dividend | 0 |
| Forward Dividend | 5.88e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|